Bruker Corp appoints Thierry L. Bernard to board

By Chris Stiles • Wednesday, April 01 11:59 • Permanent Link

Bruker Corp. appointed Thierry L. Bernard to its board of directors, effective April 1, 2026, adding a life-science tools and diagnostics executive with experience at Qiagen, bioMérieux and Neogen.

Bernard is currently chief executive officer of Qiagen, a role he has held since 2019 after joining the company in 2015 to lead its molecular diagnostics business. He has said he intends to step down as CEO once a successor is named. Before Qiagen, he spent 15 years at bioMérieux in roles that included corporate vice president for global commercial operations, investor relations and the Greater China region.

Bruker said Bernard also became chair of the U.S. trade industry association AdvaMedDx in 2023 and joined Neogen’s board in 2024.

The appointment expands Bruker’s board with an executive whose background spans diagnostics, international commercial operations and industry leadership. The company said it is seeking profitable growth and faster margin expansion as it develops its position in life-science research, biopharma and diagnostic solutions. As a result of these announcements, the company's shares have moved -1.28% on the market, and are now trading at a price of $35.34. For the full picture, make sure to review BRUKER CORP's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.